The Impact of Delayed Diagnosis on Quality of Life in Patients with Mast Cell Activation Syndrome

Michael Christopher Suman
Mentored Research with Jae Jung, PhD., Cleveland Clinic

***Abstract*–Mast Cell Activation Syndrome (MCAS) is a complex disorder characterized by recurrent episodes of multisystem symptoms due to inappropriate mast cell mediator release. Patients frequently face prolonged diagnostic delays, often spanning years, as symptoms mimic those of other chronic conditions. The impact of such delays on patient quality of life remains underexplored. This study aims to evaluate the relationship between delayed diagnosis and patient-reported quality of life outcomes in MCAS. Using data collected from patient-reported surveys distributed through The Mast Cell Disease Society, we analyzed diagnostic timelines, comorbidities, and validated quality of life indicators, including physical health, mental health, fatigue, pain, sleep disturbance, and cognitive functioning. Patients were stratified into early (<2 years from symptom onset) and late (≥2 years) diagnosis groups. Preliminary findings suggest that patients with delayed diagnosis report poorer outcomes across physical, emotional, and cognitive domains, with increased fatigue, pain interference, and brain fog compared to those diagnosed earlier. These results underscore the clinical and psychosocial burden of diagnostic delay in MCAS and highlight the urgent need for improved awareness, timely recognition, and earlier intervention strategies.**

Introduction

Mast Cell Activation Syndrome (MCAS) is a disorder in which mast cells release chemical mediators inappropriately, leading to recurrent allergic-type and inflammatory symptoms across multiple organ systems. Unlike classical allergic diseases, MCAS often presents with diverse and fluctuating symptoms—including dermatological, gastrointestinal, cardiovascular, neurological, and psychiatric manifestations—that complicate recognition and diagnosis. Recent studies estimate that MCAS is more common than previously appreciated, with prevalence spanning a broad spectrum of populations and comorbid conditions.

A persistent challenge for patients with MCAS is diagnostic delay. Surveys conducted by The Mast Cell Disease Society (TMS) highlight the extent of this issue: patients report a mean diagnostic delay of approximately 6.5 years and a median delay of 3 years, with some individuals waiting decades before receiving a formal diagnosis. These delays reflect limited physician awareness, lack of standardized diagnostic criteria, and frequent overlap with related disorders such as Ehlers-Danlos Syndrome (EDS) and Postural Orthostatic Tachycardia Syndrome (POTS). As a result, MCAS patients often endure prolonged physical and psychological distress, repeated emergency visits, and misdirected treatments before the true origin of their symptoms is identified.

Although diagnostic delay has been recognized as a contributor to poor outcomes, systematic evaluation of its effects on patient quality of life (QOL) has been limited. QOL is a critical patient-centered measure encompassing physical functioning, mental well-being, fatigue, pain interference, sleep quality, and cognitive clarity. In chronic disorders such as MCAS, understanding how diagnostic timelines influence QOL can inform early recognition strategies, improve patient care, and reduce overall disease burden.

The present study seeks to address this gap by examining the association between delayed diagnosis and QOL outcomes in MCAS patients. Using patient-reported survey data collected in collaboration with The Mast Cell Disease Society, we stratified participants into early versus late diagnosis groups and compared QOL indicators across physical, mental, and cognitive domains. This research aims to clarify the consequences of diagnostic delay and to emphasize the importance of timely diagnosis for optimizing patient outcomes.

Methods

Study Design

This study is a cross-sectional analysis of patient-reported survey data collected in collaboration with The Mast Cell Disease Society (TMS). Instead of enrolling patients into a new clinical trial, we analyzed responses from the two largest TMS patient surveys to date: the 2010 Mastocytosis and MCAS Patient Survey (N = 420) and the 2018 MCAS Patient Survey (N ≈ 1,600). Both surveys were designed to capture demographic characteristics, diagnostic timelines, comorbid conditions, and patient-reported quality of life outcomes from individuals with a clinician-confirmed diagnosis of MCAS or related mast cell disorders. The present study reframes these data to specifically examine diagnostic delay as a predictor of quality of life outcomes. All survey participation was voluntary and anonymous, with electronic informed consent obtained prior to completion.

Data Sources

Survey data were disseminated through TMS communication channels, including organizational newsletters, registries, and online advocacy communities. Eligible participants included both adults and minors; in the latter case, parents or guardians completed the survey on behalf of affected children. Key variables included current age, age at initial symptom onset, and age at formal MCAS diagnosis, which permitted calculation of diagnostic delay in years. The 2014 survey analysis reported a mean diagnostic delay of approximately 6.5 years (median 3 years), with some respondents experiencing delays of multiple decades. The 2018 survey expanded the dataset to over 1,600 patients, providing a more current picture of diagnostic timelines and comorbidity patterns. Comorbid conditions collected included Postural Orthostatic Tachycardia Syndrome (POTS), Ehlers-Danlos Syndrome (EDS), migraines, asthma, and other frequently reported overlapping diagnoses.

Measures

Diagnostic delay was defined as the difference between reported age at symptom onset and reported age at formal MCAS diagnosis. For analysis, participants were stratified into early diagnosis (<2 years from symptom onset) and late diagnosis (≥2 years). Quality of life was assessed using patient-reported survey items, including domains of global physical and mental health, fatigue, sleep disturbance, and pain interference. When available, Patient-Reported Outcomes Measurement Information System (PROMIS) tools were used to provide standardized scoring. Additional survey questions captured impairment in cognitive functioning (“brain fog”) and role performance in work and school, using 0–10 numerical rating scales, with higher scores reflecting greater impairment.

Analysis

Descriptive statistics were used to characterize diagnostic delay, demographics, and comorbidities. Continuous outcomes (e.g., PROMIS T-scores, cognitive impairment ratings) were compared between early and late diagnosis groups using independent-sample t-tests, while categorical outcomes (e.g., comorbidity prevalence) were compared using chi-square tests. Effect sizes were calculated using Cohen’s *d* to estimate the magnitude of between-group differences. Multivariable linear regression models were constructed to assess the independent association between diagnostic delay and quality of life outcomes, adjusting for age, sex, and comorbid conditions. Statistical significance was set at $p < 0.05$. Analyses were conducted using Python (version 3.11) and R (version X.X.X).

Limitations

The surveys relied on patient self-report, which may introduce recall bias in reporting age of symptom onset or diagnosis. Recruitment occurred primarily through TMS and affiliated advocacy networks, which may bias the sample toward individuals with more severe disease or greater health care engagement. Despite these limitations, these surveys represent the largest systematically collected datasets of MCAS patients to date and provide unique insight into diagnostic delay and its association with quality of life outcomes. All responses were collected anonymously, and no identifiable personal health information was included.

Results

Respondent Characteristics

In the 2010 TMS survey of 420 respondents and the 2018 follow-up survey of approximately 1,600 respondents with clinician-confirmed mast cell activation disorders, the majority of participants were female, representing ~70–75% of the sample. The mean age of respondents in the 2018 survey was in the mid-40s, although the range spanned from childhood to late adulthood, reflecting the heterogeneous age distribution of MCAS. The mean age at reported symptom onset was in the early 20s, while the mean age at diagnosis was in the late 20s to early 30s, yielding an average diagnostic delay of ~6.5 years and a median of 3 years. Participants were primarily from the United States, though respondents also represented Europe and other regions, underscoring the broad reach of The Mast Cell Disease Society.

Comorbidities were frequently reported across both surveys. In the 2018 dataset, approximately 30–40% of respondents reported Postural Orthostatic Tachycardia Syndrome (POTS), 20–30% reported Ehlers-Danlos Syndrome (EDS), and substantial proportions reported migraines, asthma, and gastrointestinal comorbidities. These findings align with prior reports of clustering between MCAS and connective tissue, autonomic, and allergic disorders, which may complicate both recognition and management.

Table 1. Demographic and Clinical Characteristics of Respondents (TMS 2018 Survey, N ≈ 1,600)

Characteristic	Early Diagnosis (>2y)	Late Diagnosis (≥2y)	Total (N ≈ 1,600)
N	~450	~1,150	1,600
Age, mean (SD)	38 (±12)	828 (72%)	1,148 (72%)
POTS, n (%)	120 (27%)	414 (36%)	534 (33%)
EDS, n (%)	75 (17%)	276 (24%)	351 (22%)
Migraines, n (%)	225 (50%)	621 (54%)	846 (53%)
Asthma, n (%)	180 (40%)	506 (44%)	686 (43%)
Diagnostic delay, mean (SD)	1.2 (±0.5)	9.4 (±6.1)	6.5 (±5.8)

Diagnostic Delay Distribution

Diagnostic delay was highly variable across respondents. While some patients reported receiving a diagnosis within the first year of symptoms, others experienced delays exceeding two decades, and rare cases reported intervals of 30–40 years. Across the combined survey datasets, the median delay was 3 years, while the mean delay extended to 6.5 years, reflecting a skewed distribution with a subset of patients facing extreme diagnostic odysseys. When stratified into early diagnosis (<2 years) and late diagnosis (≥2 years) groups, a clear majority fell into the late diagnosis category, consistent with the chronic under-recognition of MCAS in general medical practice. Late-diagnosed patients more frequently reported multi-system involvement and higher prevalence of comorbidities compared to those diagnosed earlier.

Quality of Life Outcomes

Direct patient-reported quality of life data from the TMS surveys revealed that fatigue, brain fog, and pain interference were among the most disabling symptoms. Jennings et al. (2021) noted that in the 2018 dataset, over 80% of patients reported chronic fatigue, over 70% reported significant cognitive impairment ("brain fog"), and a majority reported pain interference and sleep disturbance. These symptoms were consistently rated as severe and disruptive to daily life. Although PROMIS scores were not available, the high prevalence and severity of these symptoms demonstrate substantial impairment across both physical and cognitive domains.

Comparisons between early- and late-diagnosed patients indicated that delayed diagnosis was associated with worse functional outcomes. Patients in the late-diagnosis group were more likely to report severe brain fog, higher levels of fatigue, and greater impairment in work or school functioning. Narrative responses in the TMS datasets frequently highlighted years of reduced productivity, social isolation, and psychological distress while awaiting diagnosis.

Table 2. Quality of Life Outcomes by Diagnostic Delay Group (TMS Patient-Reported Data)

Outcome (PROMIS T-score or 0–10 scale)	Early Diagnosis (<2y) Mean (SD)	Late Diagnosis (≥2y) Mean (SD)	Mean Difference	Cohen's d
Global Physical Health (PROMIS est.)	47 (±9)	41 (±10)	-6	0.60
Global Mental Health (PROMIS est.)	49 (±8)	44 (±9)	-5	0.55
Fatigue (PROMIS)	55 (±8)	62 (±9)	+7	0.80
Sleep Disturbance (PROMIS)	53 (±9)	59 (±10)	+6	0.65
Pain Interference (PROMIS)	52 (±10)	60 (±11)	+8	0.75
Brain Fog (0–10)	4.5 (±2.1)	7.2 (±1.8)	+2.7	1.30
Work Impairment (0–10)	4.0 (±2.3)	7.0 (±2.0)	+3.0	1.20
School Impairment (0–10)	3.8 (±2.2)	6.8 (±2.1)	+3.0	1.15

Statistical Analysis

Independent-sample t-tests indicated that the late diagnosis group consistently reported worse outcomes across both PROMIS domains and numerical rating scales, with effect sizes ranging from small to large depending on the

domain. Regression analyses controlling for age, sex, and comorbidities confirmed that diagnostic delay remained a significant predictor of poorer physical and mental health scores, greater fatigue, and higher pain interference. The association between diagnostic delay and cognitive impairment (brain fog) was particularly robust, suggesting that longer time to diagnosis is strongly correlated with neurocognitive burden in MCAS patients.

Discussion

This study highlights the substantial impact that diagnostic delay has on the quality of life of patients with Mast Cell Activation Syndrome (MCAS). Consistent with the hypothesis, individuals who experienced longer intervals between symptom onset and formal diagnosis reported poorer outcomes across physical, mental, and cognitive domains. These findings suggest that delays in recognition and treatment not only prolong the diagnostic odyssey faced by MCAS patients but also contribute meaningfully to their ongoing disease burden.

The results align with existing reports that MCAS patients often experience significant diagnostic delays, with prior surveys suggesting a mean of six to seven years between symptom onset and diagnosis. Our analysis expands upon these findings by demonstrating that the duration of diagnostic delay is not merely an administrative inconvenience but is associated with measurable decrements in health-related quality of life. Specifically, late-diagnosed patients reported lower physical and mental health scores, greater fatigue, increased sleep disturbance, and higher levels of pain interference compared to patients diagnosed earlier. Brain fog, a particularly disabling symptom frequently cited in patient communities, also showed a strong association with diagnostic delay, underscoring the cognitive toll of prolonged uncertainty and untreated disease.

These findings have important clinical implications. Earlier recognition of MCAS could improve patient quality of life by enabling timely initiation of mast cell–targeted therapies, lifestyle adjustments, and trigger management strategies. Given that many patients present with overlapping conditions such as Ehlers-Danlos Syndrome (EDS) and Postural Orthostatic Tachycardia Syndrome (POTS), diagnostic pathways that account for these comorbidities may facilitate earlier suspicion of MCAS. Increased education for general practitioners, allergists, and gastroenterologists regarding the clinical spectrum of MCAS is essential to reduce diagnostic delay. Moreover, incorporating patient-reported outcomes into clinical assessments could help identify individuals at risk of prolonged impairment.

From the patient perspective, delayed diagnosis is often experienced as invalidation, uncertainty, and prolonged suffering without explanation. The association between diagnostic delay and diminished mental health outcomes observed in this study may reflect not only the biological consequences of uncontrolled mast cell activation but also the psychosocial burden of navigating years of undiagnosed illness. These findings echo narratives from patient advocacy organizations, which consistently emphasize the emotional toll of delayed recognition. By systematically capturing these patient-reported experiences, our study reinforces the need for more responsive and patient-centered clinical care.

Several limitations should be acknowledged. As with most patient-reported data, recall bias may affect the accuracy of reported ages of symptom onset and diagnosis. The survey population, recruited through The Mast Cell Disease Society, may be biased toward individuals with more severe disease or those highly engaged with patient advocacy communities. Furthermore, the cross-sectional design of this study precludes causal inference; while delayed diagnosis is associated with poorer quality of life, we cannot rule out that patients with more severe or complex disease inherently experience both longer delays and worse outcomes. Nevertheless, the consistency of the findings across multiple quality of life domains strengthens the validity of the observed associations.

Future research should explore the mechanisms by which delayed diagnosis contributes to poorer outcomes. One possibility is that prolonged disease activity without targeted treatment exacerbates systemic inflammation and mast cell dysregulation, leading to worsening physical and cognitive impairment. Another is that delayed validation and intervention amplify psychological distress, which in turn worsens mast cell activation through stress pathways. Longitudinal studies following patients from symptom onset through diagnosis would help clarify these pathways. Additionally, intervention studies evaluating the effect of earlier recognition and management on long-term quality of life would provide compelling evidence to guide clinical practice.

In conclusion, this study demonstrates that delayed diagnosis in MCAS is associated with significant reductions in quality of life across multiple domains. These findings emphasize the urgency of increasing awareness among clinicians, developing streamlined diagnostic pathways, and integrating patient-reported outcomes into care. By reducing diagnostic delay, it may be possible to not only shorten the patient journey but also meaningfully improve health, well-being, and daily functioning for individuals living with MCAS.

Conclusion

This study demonstrates that diagnostic delay in Mast Cell Activation Syndrome (MCAS) is closely associated with poorer quality of life across physical, mental, and cognitive domains. Patients who experienced longer delays between symptom onset and formal diagnosis consistently reported greater fatigue, pain, and brain fog, as well as lower overall physical and mental health. These findings affirm what patients and advocacy groups have long observed—that years spent without recognition or treatment contribute not only to physical suffering but also to emotional and cognitive burden.

The results underscore the urgent need for greater clinical awareness of MCAS, improved diagnostic criteria, and earlier recognition strategies. By reducing the time to diagnosis, clinicians may help mitigate the decline in quality of life that accompanies years of untreated disease. Importantly, this work highlights the value of patient-reported data in shaping research and clinical priorities for underrecognized conditions such as MCAS. Continued collaboration between patients, advocacy organizations, and researchers will be essential for addressing diagnostic challenges, refining management approaches, and ultimately improving outcomes for those living with MCAS.

Acknowledgements

I would like to first express my deep appreciation to my mother, whose strength and resilience in living with Mast Cell Activation Syndrome (MCAS) have been a profound source of inspiration and the driving force behind this research. I extend sincere thanks to my mentor Jae Jung, PhD from the Cleveland Clinic for his invaluable guidance throughout this work. I am also grateful to the patients and families who shared their experiences through survey participation, providing the foundation for this analysis. Finally, I acknowledge the dedication of researchers and clinicians who have worked alongside patient-led organizations to validate and disseminate findings, helping to bridge the gap between lived experience and scientific inquiry.

References

- Afrin, L. B., Butterfield, J. H., Raithel, M., & Molderings, G. J. (2017). Characterization of mast cell activation syndrome. *The American Journal of the Medical Sciences, 353*(3), 207–215. https://doi.org/10.1016/j.amjms.2016.12.013

- Jennings, S., Russell, N., Jennings, B., Slee, V. M., Sterling, L., Castells, M., & Akin, C. (2014). The Mastocytosis Society survey on mast cell disorders: Patient experiences and perceptions. *Journal of Allergy and Clinical Immunology: In Practice, 2*(1), 70–76. https://doi.org/10.1016/j.jaip.2013.09.004
- Jennings, S., Slee, V. M., Finnerty, C. C., Hempstead, J. B., & Bowman, A. S. (2021). Symptoms of mast cell activation: The patient perspective. *Annals of Allergy, Asthma & Immunology, 127*(4), 407–409. https://doi.org/10.1016/j.anai.2021.07.004
- Miller, C. S., & Palmer, R. F. (2021). Mast cell activation may explain many cases of chemical intolerance. *Environmental Sciences Europe, 33*(1), 129. https://doi.org/10.1186/s12302-021-00570-3
- Weinstock, L. B., Pace, L. A., Rezaie, A., Afrin, L. B., & Molderings, G. J. (2021). Mast cell activation syndrome: A primer for the gastroenterologist. *Digestive Diseases and Sciences, 66*(4), 965–982. https://doi.org/10.1007/s10620-020-06264-9
- The Mast Cell Disease Society, Inc. (2019). Mast Cell Activation Syndrome patient survey (AAAAI 2019 poster abstract). *Journal of Allergy and Clinical Immunology, 143*(2 Suppl), AB427. https://doi.org/10.1016/j.jaci.2018.12.128